SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors used off-label to mimic exercise-induced metabolic effects and support mitochondrial health. Users typically run daily doses ranging from 100 µg to 50 mg, with 500 µg being the most common community protocol, while clinician-tier guidance suggests 1.5 mg twice daily for six to eight weeks. The primary tradeoff is that the evidence base for this compound remains thin, as all human use is off-label and exploratory indications lack published trial results. While sleep and dream changes are occasionally reported, injection-site reactions and gastrointestinal issues have not been a consistent theme.
Data last updated
Measured on 3 of 6 axes
Evidence shape
SLU-PP-332 currently lacks any human clinical evidence, as all existing research is restricted to preclinical and mechanistic studies. There are zero registered human trials for this peptide, meaning no data exists regarding its safety, efficacy, or pharmacokinetics in human subjects. Because the current body of evidence is entirely confined to laboratory models, any claims regarding its application in humans remain speculative and unsupported by clinical literature.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How SLU-PP-332 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
In the single source consulted for this tier, the dose is 1.5 mg taken orally twice daily, with no cycling protocol reported.
Most users who specified a schedule take it daily, typically around 2 mg, while a smaller group doses twice daily at about 5 mg; many others report taking 500 mcg without a set schedule.